Fractyl Health

#FractylHealthNews: We’re thrilled to share the FDA has granted Breakthrough Device Designation for Fractyl Health’s Revita in weight maintenance after discontinuation of #GLP1 drugs. This designation is given to expedite review of promising technologies that can improve the lives of people with life-threatening or debilitating conditions. Learn more: https://bit.ly/4c7ViZd

We had a wonderful time meeting with key stakeholders from around the world at this year’s American Diabetes Association (ADA) 84th Scientific Sessions.     To read about the data we presented for our preclinical product candidate REJUVA® which was selected as the number one abstract out of 8,000 submissions by the Scientific Sessions Meeting Planning Committee, click here: https://lnkd.in/eTVrZWEf   To hear a recap of our KOL event with Dr. David D’Alessio, visit the IR page on Fractyl.com.     We look forward to seeing you again next year.     *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies    #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech

BREAKING NEWS: Fractyl Health is pleased to announce we will be accelerating our REMAIN 1 #clinicaltrial, studying our novel device’s efficacy in maintaining #weightloss following the discontinuation of GLP-1 therapy. We expect to report data starting in Q4 2024.    We also announced an amendment to our REVITALIZE 1 study, expanding eligibility to patients with #T2D who are inadequately controlled on any glucose lowering agent – including GLP-1 agonists – increasing our potential treatment population in the United States by nearly six-fold.    For the full #announcement, including a quote from our co-founder, read our full release: https://lnkd.in/gNS6D7DC

We’re thrilled to share that our oral presentation was chosen as noteworthy and one of eight Presidents’ Select Abstracts at this year’s @American Diabetes Association Scientific Sessions.    Our co-founder and CEO Harith Rajagopalan shared exciting new preclinical data from our investigational #genetherapy program REJUVA®.    For more information: https://lnkd.in/eTVrZWEf   *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies    #ADASciSessions #ADA2024 

Join us at the American Diabetes Association’s 84th Annual Scientific Sessions for a KOL discussion and Q&A session with Dr. David A. D’Alessio (Duke University School of Medicine) on Monday, June 24 from 7:00 AM – 8:00 AM ET.    Our session will feature insights on the unmet medical need and evolving treatment landscape for patients living with #obesity and #T2D. Meet with several members from our management team who will discuss Fractyl’s novel platforms.     RSVP to reserve your spot:  https://lnkd.in/eig5dT8a     A live webcast will be available on our website for those joining us virtually.    #ADASciSessions #ADA2024

The American Diabetes Association (ADA) 84th Scientific Sessions starts today in Orlando, Florida.    We will be presenting new preclinical data for our investigational product REJUVA® on Sunday, June 23rd, from 1:30-1:45 p.m. ET, in the Valencia Ballroom. This abstract was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight President’s Select Abstracts. #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech    *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies.     

We are excited to join healthcare professionals and patients from around the world to learn more about the cutting-edge research and advancements in treatments at the American Diabetes Association (ADA) 84th Scientific Sessions, June 21-24, 2024, in Orlando, Florida. We will be presenting new preclinical data for our investigational product REJUVA® on Sunday, June 23rd, from 1:30-1:45 p.m. ET, in the Valencia Ballroom. This abstract was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight President’s Select Abstracts. #ADA2024 #ADAScientificSessions #Fractyl #obesity #type2diabetes #T2D #biotech *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies.

We are thrilled to share this exciting coverage on today's Causes or Cures podcast. ErinKate Stair interviewed Harith Rajagopalan who dives into Fractyl Health's multifaceted approach to tackling metabolic diseases, including #obesity and #type2diabetes. https://lnkd.in/e3VBUpKr

Fractyl Health, Inc. (Nasdaq: GUTS) today announced that it will present new preclinical obesity data from its pancreatic gene therapy platform, Rejuva®, at the upcoming American Diabetes Association (ADA)’s 84th Scientific Sessions taking place June 21-24, 2024 in Orlando, FL. https://lnkd.in/euCWK-yh  #ADA2024 #obesity #type2diabetes #biotech      *The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. 

At #DDW2024, Fractyl Health, Inc. (Nasdaq: GUTS) shared our latest developments with the scientific and medical community. We presented new preclinical data on liver metabolism in a diet induced obesity model and the potential of Rejuva® to durably impact obesity      The plenary presentation was delivered by Harith Rajagopalan, CEO of Fractyl Health. https://lnkd.in/edBc3dqY #type2diabetes #health #obesity #genetherapy #biotech     *The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use.